ILT3-binding agents and methods of use thereof

Patent metadata

Field	Value
Publication number	US-12187796-B2
Application number	US-202318364285-A
Country	US
Kind code	B2
Filing date	Aug 2, 2023
Priority date	Dec 19, 2019
Publication date	Jan 7, 2025
Grant date	Jan 7, 2025

Abstract

The present disclosure provides binding agents, such as antibodies, that specifically bind ILT3, including human ILT3, as well as compositions comprising the binding agents, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising the binding agents.

First claim

What is claimed:

1. A binding agent that specifically binds human immunoglobulin-like transcript 3 (ILT3), comprising:
(a) a heavy chain variable region (VH) comprising a VH-complementarity determining region (CDR) 1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO: 117 and a light chain variable region (VL) comprising a VL-complementarity determining region (CDR) 1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO: 118;
(b) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO: 119 and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO:120;
(c) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO: 109 and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO:110;
(d) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO:113 and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO:114;
(e) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO:115 and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO: 116; or
(f) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO: 121 and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO:122.

2. The binding agent of claim 1 , wherein:
(a) the VH comprises the VH-CDR1, the VH-CDR2, and the VH-CDR3 from the amino acid sequence of SEQ ID NO:117; and the VL comprises the VL-CDR1, the VL-CDR2, and the VL-CDR3 from the amino acid sequence of SEQ ID NO: 118, and wherein
(i) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:71, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:72, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:73, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 74, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:75, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:76;
(ii) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:77, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:78, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:73, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 74, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:75, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:76;
(iii) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:71, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:79, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:73, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 74, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:75, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:76;
(iv) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:80, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:72, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:73, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 74, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:75, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:76; or
(v) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:81, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:82, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:83, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 84, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:85, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:86; or

(b) the VH comprises the VH-CDR1, the VH-CDR2, and the VH-CDR3 from the amino acid sequence of SEQ ID NO:119; and the VL comprises the VL-CDR1, the VL-CDR2, and the VL-CDR3 from the amino acid sequence of SEQ ID NO:120, and wherein
(i) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:27, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:87, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:88, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 89, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:90, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:91;
(ii) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:33, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:92, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:88, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 89, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:90, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:91;
(iii) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:27, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:93, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:88, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 89, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:90, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:91;
(iv) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:36, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:87, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:88, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 89, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:90, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:91; or
(v) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:37, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:94, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:95, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 96, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:97, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:98; or

(c) the VH comprises the VH-CDR1, the VH-CDR2, and the VH-CDR3 from the amino acid sequence of SEQ ID NO:109; and the VL comprises the VL-CDR1, the VL-CDR2, and the VL-CDR3 from the amino acid sequence of SEQ ID NO:110, and wherein
(i) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:11, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:12, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:13, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 14, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:15, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:16;
(ii) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:17, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:18, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:13, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 14, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO: 15, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO: 16;
(iii) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:11, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO: 19, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:13, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 14, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO: 15, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:16;
(iv) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:20, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:12, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO: 13, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 14, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:15, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:16; or
(v) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:21, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:22, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:23, the VL-CDR1 comprises the amino acid se

Assignees

• Ngm Biopharmaceuticals Inc

Inventors

• Crawley Suzanne Christine
• Hsu Jer-Yuan
• Kaplan Daniel David
• Li Betty Chan
• Lin Vicky Yi-Bing
• Malmersjö Seth
• Paavola Kevin James
• Roda Julie Michelle
• Wang Yan

Classifications

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title